Medicofarma Biotech at a glance
Medicofarma Biotech is a leading R&D company dedicated to designing, refining, and introducing innovative medications that address critical unmet needs in modern medicine. With two state-of-the-art research centers, including one GLP-certified, and an interdisciplinary team of 20 experienced scientists – 50% of whom hold PhD degrees – we are at the forefront of medical research and development.
What is Medicofarma Biotech mission?
The company mission is to transform the prevention and treatment of complex diseases by focusing on areas of high clinical need. We are committed to improving the lives of patients suffering from various oncological conditions, such as glioma, ovarian cancer, hepatic cancer, and breast cancer, as well as addressing gastrointestinal issues, including oral diseases and IBS.
To achieve these strategic goals, Medicofarma Biotech actively collaborates with esteemed Polish and European partners, including international clinical and research centers in Berlin (DE), Bydgoszcz, Poznan, and Krakow (PL). In recognition of the innovative nature of our research, Medicofarma Biotech has been a member of the European Federation of Biotechnology since early 2023.
Medicofarma Biotech is dedicated to driving advancements in healthcare and impacting patient outcomes worldwide.
Next-Generation Glioblastoma Treatment: RNA-Based Anti-Cancer Therapy
Our leading project: “Anti-cancer therapy based on RNA technology,” focuses on glioblastoma (GBM), a rare and malignant disease affecting over 100,000 people worldwide each year. Despite aggressive treatment methods like surgery, chemotherapy, and radiotherapy, the median survival rate for GBM patients remains just 14-18 months.
Developing First-in-Class Therapeutics: This project aims to develop a new class of therapeutics—termed „first-in-class”—leveraging RNA technology to modify the extracellular matrix. These innovative treatments could address unmet medical needs, including glioma and other malignant tumors.
Targeted Therapy Candidates: We have successfully developed therapeutic candidates that specifically bind to and silence their targets.
Enhanced Stability with Lipid Nanoparticles: These molecules have been encapsulated in lipid nanoparticles, which dramatically improve the stability of the active substances while maintaining an excellent safety profile.
Patent Protection and Preclinical Progress: The compounds are currently the subject of multiple pending Polish and PCT patents. Their activity has been confirmed in vitro, and the company is now progressing to the in vivo preclinical phase.
Pioneering Clinical Trials: As part of this project, the company plans to conduct a „first-in-human” clinical trial, marking a significant step forward in the development of effective glioblastoma treatments.
Innovative IBS Treatment: Vitamin Drink with Regenerative Potential
The second key project: a groundbreaking Vitamin Drink Enriched with Natural Compounds—the world’s first product to utilize a patented substance with regenerative potential for irritable bowel syndrome (IBS). This innovative solution is being developed through a collaborative effort between Medicofarma S.A., Medicofarma Biotech S.A., and the Poznań University of Life Sciences.
The project aims to revolutionize the treatment of IBS by:
Identifying IBS Biomarkers: the focus on biomarkers related to inflammation, stress, and specific IBS subtypes to better understand the disease.
Assessing Effectiveness: the vitamin drink is designed to alleviate IBS symptoms, and its efficacy will be scientifically evaluated through comprehensive testing.
Advanced Molecular Analysis: By conducting transcriptome and metabolome analyses, the company aims to detect subtle molecular changes—such as a confirmation of the therapeutic effects of this functional drink, setting a new standard in the management of IBS.
*For more info please visit: https://medicofarmabiotech.pl/